65,700 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB bought a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 65,700 shares of the biotechnology company's stock, valued at approximately $1,127,000.

Several other large investors also recently modified their holdings of ADMA. State Street Corp increased its stake in shares of ADMA Biologics by 61.4% in the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company's stock worth $259,970,000 after buying an additional 4,945,063 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of ADMA Biologics by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company's stock valued at $107,606,000 after purchasing an additional 137,989 shares in the last quarter. Perpetual Ltd bought a new position in shares of ADMA Biologics during the fourth quarter worth about $62,300,000. Lord Abbett & CO. LLC acquired a new position in ADMA Biologics in the third quarter worth about $61,858,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after buying an additional 2,613,482 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock traded down $0.52 on Monday, reaching $15.87. 2,953,128 shares of the company were exchanged, compared to its average volume of 2,284,203. The firm has a market cap of $3.75 billion, a price-to-earnings ratio of 56.66 and a beta of 0.75. ADMA Biologics, Inc. has a 1-year low of $5.52 and a 1-year high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company's 50-day moving average is $16.73 and its two-hundred day moving average is $17.99.

Remove Ads

Analyst Ratings Changes

A number of research analysts have commented on ADMA shares. HC Wainwright increased their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Raymond James lifted their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.